Investor Presentation Full Year 2021

72 Investor presentation Full year 2021 Biopharm sales growth of 4% driven by commercial execution and key brands EsperoctⓇ and Refixia® NovoSevenⓇ and NorditropinⓇ account for ~75% of Biopharm sales Added sales within rare blood disorders driven by new launches DKK billion 25 -16% -1% 4% 1% 4% 20 15 10 5 DKK billion 25% 25% 4% 10.2 9.7 0 2017 2018 2019 2020 2021 FY Haemophilia Haemophilia NovoSevenⓇ 2020 A B FY 2021 NovoSeven Ⓡ Other haemophilia products Norditropin Ⓡ Other biopharm Growth at CER Growth at CER Note: Company reported sales; CER: Constant exchange rates; 1Other haemophilia products primarily consists of Vagifem® and Activelle® Novo NordiskⓇ

View entire presentation